![]() ![]() This removes a powerful variable due to some tests being very specialised and results from different labs can vary. The powerful aspect of this study is that all of the tests were conducted with the same lab tests. Fourteen different aspects of immune protection were measured, including antibody response and how different kinds of immune cells react. The above study compares 3 different kinds of COVID vaccines, two mRNA-based vaccines, a viral vector vaccine (where a harmless virus which carries the SARS-CoV-2 spike protein gene is injected as a vaccine, with the patient being tricked into making the COVID spike protein) and a genetically engineered spike protein injected into recipients. ![]() The paper “ Humoral and cellular immune memory to four COVID-19 vaccines” compares the BioNTech/Pfizer, Moderna, Johnson & Johnson ( JNJ ) and Novavax COVID vaccines. Recently prestigious science journal Nature highlighted a paper recently published (but not yet reviewed) on bioRxiv. I also comment on the Novavax technology in reaching conclusions about prospects for the company. Here I comment on comparison between four much discussed vaccines, which shows the Novavax vaccine NVX-CoV2373, while highly effective, falling short of the mRNA-based vaccines of Pfizer ( PFE )/BioNTech ( BNTX ) and Moderna ( MRNA ) in specific areas. As the COVID vaccine story matures some things are becoming clearer. ![]() There has been a lot of hype in the COVID vaccine story and Novavax ( NASDAQ: NVAX) is a company that has attracted more than its share of attention. There is no substitute for facts to help an investor make decisions. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |